Sort   by:  
 Page size 
UnknownCalibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation.
Not available
S-EPMC8671391 | biostudies-literature
UnknownUse of placebos in Phase 1 preventive HIV vaccine clinical trials.
Not available
S-EPMC4554766 | biostudies-literature
UnknownAdults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
Not available
S-EPMC10684488 | biostudies-literature
UnknownCell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
Not available
S-EPMC5652289 | biostudies-literature
UnknownAssociation between COVID-19 vaccine efficacy and epidemic force of infection.
Not available
S-EPMC12921246 | biostudies-literature
UnknownPharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.
Not available
S-EPMC11837431 | biostudies-literature
UnknownPharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
Not available
S-EPMC7841500 | biostudies-literature
UnknownPredictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.
Not available
S-EPMC5319823 | biostudies-literature
UnknownFixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
Not available
S-EPMC12205768 | biostudies-literature
UnknownBaseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.
Not available
S-EPMC9520208 | biostudies-literature
Sort   by:  
 Page size